The company benefits from a robust pipeline and recurring revenues as a MedTech leader, positioning it for sustained above-market growth, while efficiency gains, vertical integration, and M&A drive expanding profit margins. Key revenue drivers include robotic surgery (29%), surfaces & support (23%), and interventional & surgical applications (21%).
Cyborg Score Rationale
UFP beat Wall Street expectations in Q3 2025 with 6.5% year-over-year revenue growth to $154.6 million and non-GAAP EPS 10% above consensus. However, high customer concentration creates revenue volatility and margin pressure, while reliance on acquisitions heightens integration risks.
Top Insights
UFP serves 26 of the top 30 medical OEMs across 21 manufacturing facilities and 6 innovation centers.
The company targets 17-20% adjusted operating margin over the next three to five years.
At $598 million in annual revenue, UFP remains a small company in an industry where scale matters, making it difficult to build trust with complex, regulated healthcare customers.
Analyst price targets were recently increased 14% to $336.09 per share as of February 2026.
Named Competitors
Integer Holdings Corporation — Diversified medical component manufacturer (ITGR)
Nordson Medical — Medical components and systems (NDSN)
Viant Medical — Private medical device contract manufacturer
Medbio — Private medical device solutions provider
Recent Developments
(February 2026) CEO succession and executive compensation finalized with updated investor strategy presentation
(February 2026) Analyst price targets increased 14% to $336.09, reflecting confidence in MedTech growth
(November 2025) Q3 revenue beat expectations at $154.6M, up 6.5% YoY with strong EPS performance
Open the full interactive UFP Technologies, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.